The fear of Zika virus infection, has not been reported in India, but the America is the first country in the world to test not just one but two vaccines against the virus that is causing nightmares.
The globally gigantic ‘Zika biotech moment for India’ couldn’t have come up in the more righteous time, the Department of Biotechnology (DBT) setup is celebrating its 30th anniversary in the country, under the tech savvy late Prime Minister Rajiv Gandhi’s leadership which had started in the year 1986.
The old times of Indian land and people are seeing a new transformation and innovation with Mr. Narendra Modi, who had introduced us the ‘Make in India‘ and ‘Start-up India’ challenge, who is the current tech savvy Prime Minister of India.
Bharat Biotech International Limited is the company that developed the Zika virus vaccine in Hyderabad, which has marked a milestone beyond the catchy slogan of prime minister’s ‘make in India’ and also the patent being an Indian. Manufacturing in India requires an License, the manufacturing license in India is essential to produce any medical device, drugs etc. There is a list for the notified medical devices to know under which category the product is listed.
The discovery of Zika virus vaccine began in 1996 with a Tamilian farmer’s son who is now the chairman-cum-managing director of Bharat Biotech was forced by his mom to reunite with his family in India, Krishna Ella was trained at the University of Wisconsin-Madison in USA as a molecular biologist there made a decision to return back to India.
Other News
India Medical Device Pricing Strategy: Ensuring Growth & Affordability
India’s National Pharmaceutical Pricing Authority (NPPA) is developing a specialized India medical device pricing strategy for medical devices, transitioning away from the conventional drug-centric framework. This innovative strategy will incorporate international pricing tactics tailored to […]
Read MoreImports of High-Value Medical Equipment
High-Value Medical Equipment The Central Drugs Standard Control Organization (CDSCO) and the Central Board of Indirect Taxes & Customs have released a new circular, “F.No.401/40/2021-Cus.III,” detailing updated policies on the import of used high-end medical […]
Read MoreSEC Committee: Pioneering Medical Approvals
New important article released by Central Drugs Standard Control Organization (CDSCO) titled “SEC – Special Expert Committee, Medical Devices”. Key highlights include the streamlined processes for CDSCO application evaluations, preparation and significance of briefing materials, […]
Read More
ErlySign Oral Cancer Detection Technology Gets CDSCO Nod
ErlySign, a Nagpur-based biotech startup, has received approval from the Central Drugs Standard Control Organization (CDSCO) to conduct large-scale clinical trials for its novel oral cancer detection technology. The approval for ErlySign follows a rigorous […]
Read MoreAdditional Steps Announced by FDA to Modernize Clinical Trials
The U.S. Food and Drug Administration has made draft guidance available with updated recommendations for good clinical practices (GCPs), which are intended to modernize the clinical trial design and conduct while maintaining data integrity and […]
Read MoreAccreditation and Registration Numbers for Foreign Manufacturers Publication by PMDA
This article deals In accordance with the Pharmaceuticals and Medical Devices Act (PMD Act) of Japan, foreign businesses that wish to produce pharmaceuticals, quackery products, active pharmaceutical ingredients (APIs), or medical devices abroad and import […]
Read MoreBSI New Certification to Mitigate Antimicrobial Resistance Risk in Antibiotic Manufacturing
BSI, the business improvement and standards company, has developed a new certification to mitigate the risk of antimicrobial resistance (AMR) in antibiotic manufacturing. The certification, called the Minimized Risk of Antimicrobial Resistance (AMR) certification, will […]
Read More
TUV SUD Inspects IVD Medical Devices’ Cyber Security
The growing digital connectivity of medical infrastructure is resulting in complicated systems with a plethora of diverse interfaces that are potentially vulnerable to assault. The IVD requires producers to provide proof of cyber security before […]
Read More
